



(11)

EP 1 362 601 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 B1)
INID code(s) 74

(51) Int Cl.:

G01N 33/50 (2006.01)

(48) Corrigendum issued on:

28.02.2007 Bulletin 2007/09

(86) International application number:

PCT/JP2002/001562

(45) Date of publication and mention
of the grant of the patent:

03.01.2007 Bulletin 2007/01

(87) International publication number:

WO 2002/066073 (29.08.2002 Gazette 2002/35)

(21) Application number: **02700679.0**

(22) Date of filing: **21.02.2002**

(54) **METHOD OF EXAMINING EFFECT OF ANGIOGENESIS INHIBITOR MEDIATED BY THE INHIBITION OF INTEGRIN EXPRESSION**

VERFAHREN ZUR UNTERSUCHUNG DER WIRKUNG EINES ANGIOGENESIS-HEMMERS UNTER VERMITTLUNG DURCH HEMMUNG DER INTEGRIN-EXPRESSION

PROCEDE SERVANT A ANALYSER L'EFFET D'UN INHIBITEUR D'ANGIOGENESE MEDIE PAR L'INHIBITION DE L'EXPRESSION DE L'INTEGRINE

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

• **FUNAHASHI, Yasuhiro,**
c/o Eisai Co. Ltd,
Tsukuba-shi, Ibaraki 300-2635 (JP)

• **WAKABAYASHI, Toshiaki,**
c/o Eisai Co. Ltd.
Tsukuba-shi, Ibaraki 300-2635 (JP)

(30) Priority: **21.02.2001 JP 2001044646**

(43) Date of publication of application:

19.11.2003 Bulletin 2003/47

(74) Representative: **Dean, John Paul et al**
Withers & Rogers LLP
Goldings House,
2 Hays Lane
London SE1 2HW (GB)

(60) Divisional application:

06013455.8 / 1 742 052

(73) Proprietor: **Eisai Co. Ltd**

Tokyo 112-8088 (JP)

(56) References cited:

WO-A-00/41469 WO-A-98/44797
WO-A1-00/50395 WO-A1-01/56607
WO-A1-95/07276 WO-A1-99/02551
US-A- 5 843 906

(72) Inventors:

- **ONO, Naoto,**
c/o Eisai Co. Ltd, Tsukuba Res. Lab.
Tsukuba-shi,
Ibaraki 300-2635 (JP)
- **SENBA, Taro,**
c/o Eisai Co. Ltd, Tsukuba Res. Lab.
Tsukuba-shi, Ibaraki 300-2635 (JP)
- **HATA, Naoko, c/o Eisai Co. Ltd.,**
Tsukuba Res. Lab
Tsukuba-shi, Ibaraki 305-2635 (JP)

- **TRIKHA MOHIT ET AL: "Human prostate carcinoma cells express functional alpha-IIb-beta-3 integrin" CANCER RESEARCH, vol. 56, no. 21, 1996, pages 5071-5078, XP002326754 ISSN: 0008-5472**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 362 601 B8

- | | |
|--|--|
| <ul style="list-style-type: none">• VERHEUL HENK M W ET AL: "Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets" BLOOD, vol. 96, no. 13, 15 December 2000 (2000-12-15), pages 4216-4221, XP002327392 ISSN: 0006-4971 | <ul style="list-style-type: none">• VERHEUL H M ET AL: "Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JAN 2000, vol. 6, no. 1, January 2000 (2000-01), pages 166-171, XP002327393 ISSN: 1078-0432 |
|--|--|